Page last updated: 2024-11-10

tocotrienol, alpha

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-tocotrienol : A tocotrienol that is chroman-6-ol substituted by methyl groups at positions 2, 5, 7 and 8 and a farnesyl chain at position 2. It has been found in palm oil derived from Elaeis guineensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Elaeisgenus[no description available]ArecaceaeThe palm family of order Arecales, subclass Arecidae, class Liliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID5282347
CHEMBL ID120276
CHEBI ID33270
SCHEMBL ID242672
SCHEMBL ID16430461
MeSH IDM0218688

Synonyms (51)

Synonym
CHEBI:33270 ,
(2r)-2,5,7,8-tetramethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2h-chromen-6-ol
alpha-tocotrienol
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, [r-(e,e)]-
(2r,3'e,7'e)-alpha-tocotrienol
58864-81-6
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-, (2r)- (9ci)
(r)-alpha-tocotrienol
tocotrienol, alpha
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl]-, (2r)-
zeta1-tocopherol
d-alpha-tocotrienol
CHEMBL120276
LMPR02020054
2r,5,7,8-tetramethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-3,4-dihydro-2h-chromen-6-ol
(2r)-2,5,7,8-tetramethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]-3,4-dihydrochromen-6-ol
unii-b6lxl1832y
(2r)-2,5,7,8-tetramethyl-2-((3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-ol
b6lxl1832y ,
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((3e,7e)-4,8,12-trimethyl-3,7,11-tridecatrienyl)-, (2r)-
2h-1-benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-, (r-(e,e))-
alpha-tocotrienol [mi]
d-|a-tocotrienol
(2r)-2,5,7,8-tetramethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]chroman-6-ol
vitamin e (alpha-tocotrienol)
.alpha.-tocotrienol
(r)-.alpha.-tocotrienol
d-alpha tocotrienol
alpha-tocotrienol [who-dd]
(2r,3'e,7'e)-.alpha.-tocotrienol
.alpha.-tocotrienol [mi]
d-.alpha.-tocotrienol
SCHEMBL242672
tocotrienol, 5,7,8-trimethyl
HMS3650C04
SCHEMBL16430461
d-alpha-tocotrienol, analytical reference material
AKOS027326801
alpha-tocotrienol, analytical standard
delta-alpha-tocotrienol
J-010798
mfcd11045308
SR-01000946263-1
sr-01000946263
Q171833
DTXSID901019976
NCGC00253538-02
AS-78670
HY-129459
CS-0105636
alpha -tocotrienol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Although the antioxidant activity of tocotrienols is higher than that of tocopherols, tocotrienols have a lower bioavailability after oral ingestion."( Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling.
Packer, L; Rimbach, G; Weber, SU, 2001
)
0.31
"We have investigated the pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under fed and fasted conditions in eight healthy volunteers."( Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status.
Wong, JW; Yap, SP; Yuen, KH, 2001
)
0.31
"A study was conducted to evaluate the bioavailability of alpha-, gamma- and delta-tocotrienols administered via oral, intravenous, intramuscular and intraperitoneal routes in rats."( Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats.
Lim, AB; Yap, SP; Yuen, KH, 2003
)
0.32
"A single dose comparative bioavailability study was conducted to evaluate the bioavailability of tocotrienols from two self-emulsifying formulations, one of which produced an emulsion that readily lipolysed under in vitro condition (SES-A), while the other produced a finer dispersion with negligible lipolysis (SES-B) in comparison with that of a non-self-emulsifying formulation in soya oil."( Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations.
Yap, SP; Yuen, KH, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" The tocotrienol-rich fraction (TRF) of palm oil inhibited growth of MCF7 cells in both the presence and absence of estradiol with a nonlinear dose-response but such that complete suppression of growth was achieved at 8 microg/mL."( Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.
Darbre, P; Dils, R; Nesaretnam, K; Stephen, R, 1998
)
0.3
" In Experiment 2, we examined whether sesaminol caused enhanced absorption of alpha-tocopherol and alpha-tocotrienol in a dosage regimen supplying T-mix and sesaminol on alternating days and observed significantly higher levels of alpha-tocopherol and alpha-tocotrienol in rats fed sesaminol, even without simultaneous intake, compared to those in rats without sesaminol."( Effect of sesaminol on plasma and tissue alpha-tocopherol and alpha-tocotrienol concentrations in rats fed a vitamin E concentrate rich in tocotrienols.
Iizuka, Y; Ikeda, I; Ikeda, S; Yamashita, K, 2002
)
0.31
" Tocotrienols were measured in heart, liver and adipose tissue showing that chronic oral dosage delivered tocotrienols to these organs despite low or no detection of tocotrienols in plasma."( Anti-inflammatory γ- and δ-tocotrienols improve cardiovascular, liver and metabolic function in diet-induced obese rats.
Brown, L; Fong, CW; Ward, LC; Wong, WY; Yap, WN, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tocotrienolA tocol in which the hydrocarbon chain at position 2 contains three double bonds.
vitamin EAny member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
vitamin E biosynthesis (tocotrienols)113

Bioassays (31)

Assay IDTitleYearJournalArticle
AID50653Compound is evaluated for the effect on lipid metabolism in 6-week-old male chickens at a concentration of 20 ppm in the diet and measured for LDL cholesterol1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID611327Metabolic stability in human liver microsomes assessed as alpha-tocotrienol quinone level at 20 uM2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID537461Chemical stability of the compound in phosphate buffer at pH 7.4 after 24 hrs by HPLC method relative to zero time concentration2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors.
AID195001Compound is evaluated for the inhibition of cholesterol biosynthesis in isolated rat hepatocytes at the concentration 500 ug/mL1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID51430Compound is evaluated for the effect on lipid metabolism in 6-week-old male chickens at a concentration of 20 ppm in the diet and measured for total cholesterol1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID194996Inhibitory concentration required to inhibit cholesterol synthesis in isolated rat Hepatocytes1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID194999Compound is evaluated for the inhibition of cholesterol biosynthesis in isolated rat hepatocytes at the concentration 250 (ug/mL)1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID457739Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion.
AID345799Neuroprotective activity against glutamate-induced neuronal cell death in Sprague-Dawley rat primary cortical neuron at 0.25 uM pretreated for 24 hrs prior to glutamate challenge measured after 24 hrs by MTT assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults.
AID457738Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion.
AID690612Antioxidant activity assessed as ABTS+ free radical scavenging activity by TEAC assay2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Tocotrienamines and tocopheramines: reactions with radicals and metal ions.
AID690597Antioxidant activity assessed as ferric ion reducing power by FRAP method2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Tocotrienamines and tocopheramines: reactions with radicals and metal ions.
AID690600Antioxidant activity assessed as DPPH free radical scavenging activity2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Tocotrienamines and tocopheramines: reactions with radicals and metal ions.
AID611325In vivo metabolic stability in rat assessed as parent compound remaining at 5 mg/kg, iv2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID611326In vivo metabolic stability in rat assessed as parent compound remaining at 25 mg/kg, po2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID50641picomoles of mevalonic acid synthesized per minute per mg of microsomal protein1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID194998Compound is evaluated for the inhibition of cholesterol biosynthesis in isolated rat hepatocytes at the concentration 125 (ug/mL)1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID195011Percent inhibition at 250 ug/mL of binary mixtures of compound and gamma-tocotrienol on cholesterol synthesis in rat hepatocytes1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID345800Neuroprotective activity against glutamate-induced neuronal cell death in Sprague-Dawley rat primary cortical neuron at 0.25 uM administered simultaneously with glutamate after 24 hrs by MTT assay2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults.
AID86698Compound evaluated for Percent inhibition of cholesterol synthesis from HMG-CoA Reductase in HepG2 cell1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID50632Compound is evaluated for the effect on lipid metabolism in 6-week-old male chickens at a concentration of 20 ppm in the diet and measured for HDL cholesterol1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID611328Metabolic stability in mouse liver microsomes assessed as alpha-tocotrienol quinone level at 20 uM2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging.
AID86699Compound evaluated for Percent inhibition of cholesterol synthesis from [14C]acetate in HepG2 cell1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID537462Chemical stability of the compound in phosphate buffer at pH 7.4 after 1 hr by HPLC method relative to zero time concentration2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors.
AID195010Percent inhibition at 250 ug/mL of binary mixtures of compound and delta-tocotrienol on cholesterol synthesis in rat hepatocytes1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Hypocholesterolemic activity of synthetic and natural tocotrienols.
AID537457Cytotoxicity against mouse +SA cells after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.71)18.7374
1990's21 (17.95)18.2507
2000's39 (33.33)29.6817
2010's48 (41.03)24.3611
2020's7 (5.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.71 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index5.69 (4.65)
Search Engine Demand Index50.01 (26.88)
Search Engine Supply Index3.96 (0.95)

This Compound (24.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (4.24%)5.53%
Reviews1 (0.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other112 (94.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Exploratory, Double-blind, Randomized, Placebo Controlled Study of AMP-886 in the Elderly [NCT01953172]12 participants (Actual)Interventional2013-10-31Terminated(stopped due to Recruitment problems)
A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations [NCT01962363]Phase 24 participants (Actual)Interventional2013-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]